Evoke Wealth’s Takeda Pharmaceutical TAK Stock Holding History

Evoke Wealth’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-5	Closed	–	–	1125
2020 Q2	$0	Buy	+5	New	+$90	﹤0.01%	1185

Other funds holding TAK

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Evoke Wealth's TAK Position: Q3 2020 in Review

Evoke Wealth sold out of Takeda Pharmaceutical (TAK) in Q3 2020, closing a stake of 5 shares.

Evoke Wealth first reported a position in TAK in Q2 2020 and held it in 1 quarter. The position peaked at $0 in Q2 2020. 311 funds tracked by Wall St. Rank hold TAK as of Q3 2020.

Evoke Wealth reported no remaining Takeda Pharmaceutical position as of Q3 2020 after selling out during the quarter.
Evoke Wealth sold 5 Takeda Pharmaceutical shares in Q3 2020.
Evoke Wealth first reported a position in Takeda Pharmaceutical in Q2 2020 and held it in 1 quarter.
Evoke Wealth's Takeda Pharmaceutical position peaked at $0 in Q2 2020.
311 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2020.

Based on Evoke Wealth's 13F filing for Q3 2020, filed 13 Nov 2020.